KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $313.0 million.

  • Alnylam Pharmaceuticals' Free Cash Flow rose 69202.08% to $313.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.4 million, marking a year-over-year increase of 127809.87%. This contributed to the annual value of -$42.6 million for FY2024, which is 20153.53% down from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Free Cash Flow stood at $313.0 million, which was up 69202.08% from $139.4 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Free Cash Flow registered a high of $342.3 million during Q3 2023, and its lowest value of -$252.8 million during Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Free Cash Flow averaged around -$53.0 million, with its median value being -$127.3 million (2025).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Free Cash Flow tumbled by 13003.72% in 2024 and then skyrocketed by 69202.08% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Free Cash Flow stood at -$172.0 million in 2021, then rose by 10.7% to -$153.6 million in 2022, then soared by 70.64% to -$45.1 million in 2023, then tumbled by 130.04% to -$103.8 million in 2024, then surged by 401.64% to $313.0 million in 2025.
  • Its last three reported values are $313.0 million in Q3 2025, $139.4 million for Q2 2025, and -$127.3 million during Q1 2025.